{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:28:25Z","timestamp":1792736905748,"version":"4.5.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017302","name":"Barbara Ann Karmanos Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Poly-(ADP)-ribose polymerase inhibitors (PARPi) and platinum-based drugs are promising therapies for triple negative breast cancers (TNBC) with <jats:italic>BRCA1<\/jats:italic> or <jats:italic>BRCA2<\/jats:italic> loss. PARPi(s) show better efficacies when combined with platinum-based therapy, however, acquisition of PARPi resistance has been linked with co-resistance to platinum-based drugs. Here, we show that TNBCs with constitutively hyperactivated PARP-1 display greater tolerances for the PARPi olaparib and cisplatin, and respond synergistically to olaparib\/cisplatin combinations with increased cytotoxicity. Regardless of <jats:italic>BRCA1<\/jats:italic> and PARP-1 activity status, upon gaining olaparib resistance (OlaR), OlaR MDA-MB-468 (<jats:italic>BRCA1<\/jats:italic> wild-type) and SUM1315 (<jats:italic>BRCA1<\/jats:italic> mutant) TNBC cells retain cisplatin sensitivities of their isogenic parental counterparts. OlaR TNBC cells express decreased levels of PARP-1 and Pol \u03b7, a translesion-synthesis polymerase important in platinum-induced interstrand crosslink repair. Although native RAD51 recombinase levels are unaffected, anti-RAD51 immunoreactive low molecular weight sbands are exclusively detected in OlaR cells. Despite normal <jats:italic>BRCA1<\/jats:italic>, RAD51 foci formation\/recruitment to double-strand breaks are impaired in OlaR MDA-MB-468 cells, suggesting homologous-recombination impairment. RNA-seq and pathway analysis of cisplatin-affected genes revealed enrichment of G2\/M cell cycle regulation and DNA repair pathways in parental and OlaR MDA-MB-468 cells whereas parental and OlaR SUM1315 cells showed enrichment of inflammatory stress response pathways associated with TNFR1\/2, TWEAK and IL-17 signaling. These data show that TNBC models with wild type versus mutant <jats:italic>BRCA1<\/jats:italic> exhibit differences in CDDP-induced cellular response pathways, however, the CDDP-induced signaling responses remain stable across the isogenic models of OlaR from the same lineage. These data also show that adaptive OlaR does not automatically promote cisplatin resistance, implicating the potential benefit of platinum-based therapy for OlaR TNBCs.<\/jats:p>","DOI":"10.3389\/fonc.2021.694793","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T18:04:30Z","timestamp":1626977070000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells"],"prefix":"10.3389","volume":"11","author":[{"given":"Ambikai","family":"Gajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashapurna","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gurdziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen Sheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malathy P.","family":"Shekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med","article-title":"Synthetic Lethality and Cancer Therapy: Lessons Learned From the Development of PARP Inhibitors","volume":"66","author":"Lord","year":"2015","journal-title":"Ann Rev Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867323666161214114948","article-title":"Combination Platinum-Based and DNA Damage Response-Targeting Cancer Therapy: Evolution and Future Directions","volume":"24","author":"Basourakos","year":"2017","journal-title":"Curr Med Chem"},{"key":"B3","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1158\/2159-8290.CD-12-0112","article-title":"Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1","volume":"2","author":"Byers","year":"2012","journal-title":"Cancer Discov"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.382","article-title":"The Role of PARP in DNA Repair and its Therapeutic Exploitation","volume":"105","author":"Javle","year":"2011","journal-title":"Br J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3376","article-title":"New Insights Into the Molecular and Cellular Functions of Poly(ADP-Ribose) and PARPs","volume":"13","author":"Gibson","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1963","article-title":"Poly(ADP-Ribose): Novel Functions for an Old Molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2741\/2909","article-title":"The Diverse Biological Roles of Mammalian PARPs, a Small But Powerful Family of poly-ADP-ribose Polymerases","volume":"13","author":"Hassa","year":"2008","journal-title":"Front Biosci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2010.06.017","article-title":"The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets","volume":"39","author":"Krishnakumar","year":"2010","journal-title":"Mol Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrc2812","article-title":"PARP Inhibition: PARP1 and Beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.46.30069","article-title":"Poly(ADP-Ribose) Polymerase Null Mouse Cells Synthesize ADP-Ribose Polymers","volume":"273","author":"Shieh","year":"1998","journal-title":"J Biol Chem"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.25.17860","article-title":"PARP-2, A Novel Mammalian DNA Damage-Dependent Poly(ADP-Ribose) Polymerase","volume":"274","author":"Am\u00e9","year":"1999","journal-title":"J Biol Chem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2004.06.002","article-title":"PARP-1, PARP-2 and ATM in the DNA Damage Response: Functional Synergy in Mouse Development","volume":"3","author":"Huber","year":"2004","journal-title":"DNA Repair (Amst)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.193375","article-title":"The Role of ADP-ribosylation in Regulating DNA Interstrand Crosslink Repair","volume":"129","author":"Gunn","year":"2016","journal-title":"J Cell Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The Underlying Mechanism for the PARP and BRCA Synthetic Lethality: Clearing Up the Misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-11-0477","article-title":"Increased PARP-1 Association With DNA in Alkylation Damaged, PARP-Inhibited Mouse Fibroblasts","volume":"10","author":"Kedar","year":"2012","journal-title":"Mol Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Differential Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients With a Germline BRCA-Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2019.07.008","article-title":"PARP Inhibitor Resistance: A Tug-of-War in BRCA-mutated Cells","volume":"29","author":"Noordermeer","year":"2019","journal-title":"Trends Cell Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-012-0197-3","article-title":"The Role of PARP1 in the DNA Damage Response and its Application in Tumor Therapy","volume":"6","author":"Wang","year":"2012","journal-title":"Front Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201000068","article-title":"Aurora-A Expressing Tumour Cells Are Deficient for Homology-Directed DNA Double Strand-Break Repair and Sensitive to PARP Inhibition","volume":"2","author":"Sourisseau","year":"2010","journal-title":"EMBO Mol Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.2980","article-title":"Secondary Somatic Mutations Restoring BRCA1\/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas","volume":"29","author":"Norquist","year":"2011","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"B23","article-title":"Drug Synergism: Its Detection and Application","volume":"298","author":"Tallarida","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.792192","article-title":"Pharmacological Targeting of RAD6 Enzyme-Mediated Translesion Synthesis Overcomes Resistance to Platinum-Based Drugs","volume":"292","author":"Sanders","year":"2017","journal-title":"J Biol Chem"},{"key":"B25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: Ultrafast Universal RNA-Seq Aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: A Bioconductor Package for Differential Expression Analysis of Digital Gene Expression Data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1494","article-title":"Synthetic Lethality of PARP Inhibitors in Combination With MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer","volume":"78","author":"Carey","year":"2018","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.03.093","article-title":"Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated With PARP Inhibitor Resistance","volume":"23","author":"Hu","year":"2018","journal-title":"Cell Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2005.10.001","article-title":"Human DNA Polymerase Eta Promotes DNA Synthesis From Strand Invasion Intermediates of Homologous Recombination","volume":"23","author":"McIlwraith","year":"2018","journal-title":"Mol Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1021\/bi900389b","article-title":"Photoaffinity Labeling Reveals Nuclear Proteins That Uniquely Recognize cisplatin-DNA Interstrand Cross-Links","volume":"48","author":"Zhu","year":"2009","journal-title":"Biochemistry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3000","article-title":"Cisplatin Resistance Associated With PARP Hyperactivation","volume":"73","author":"Michels","year":"2013","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143390","article-title":"Platinum Salts in Patients With Breast Cancer: A Focus on Predictive Factors","volume":"20","author":"Garutti","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.19.4.2986","article-title":"Role for Caspase-Mediated Cleavage of Rad51 in Induction of Apoptosis by DNA Damage","volume":"19","author":"Huang","year":"1999","journal-title":"Mol Cell Biol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1667\/RR1129.1","article-title":"Radiation Enhances Caspase 3 Cleavage of Rad51 in BRCA2-Defective Cells","volume":"169","author":"Brown","year":"2008","journal-title":"Radiat Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109917200","article-title":"Biochemical Characterization of the Human RAD51 Protein. III. Modulation of DNA Binding by Adenosine Nucleotides","volume":"277","author":"Tombline","year":"2002","journal-title":"J Biol Chem"},{"key":"B37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/10409230903501819","article-title":"DNA Interstrand Crosslink Repair in Mammalian Cells: Step by Step","volume":"45","author":"Muniandy","year":"2010","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4161\/cc.9.4.10727","article-title":"Multiple Two-Polymerase Mechanisms in Mammalian Translesion DNA Synthesis","volume":"9","author":"Livneh","year":"2010","journal-title":"Cell Cycle"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr448","article-title":"Structure-Dependent Bypass of DNA Interstrand Crosslinks by Translesion Synthesis Polymerases","volume":"37","author":"Ho","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1021\/tx300011w","article-title":"Replication Bypass of N2\u2013deoxyguanosine Interstrand Crosslinks by Human DNA Polymerases \u03b7 and \u03b9","volume":"25","author":"Klug","year":"2012","journal-title":"Chem Res Toxicol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C100466200","article-title":"ATM Phosphorylates Histone H2AX in Response to DNA Double-Strand Breaks","volume":"276","author":"Burma","year":"2001","journal-title":"J Biol Chem"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2009.206","article-title":"PARP Is Activated at Stalled Forks to Mediate Mre11-Dependent Replication Restart\u00a0and Recombination","volume":"28","author":"Bryant","year":"2009","journal-title":"EMBO J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207491","article-title":"Ablation of PARP-1 Does Not Interfere With the Repair of DNA Double-Strand Breaks, But Compromises the Reactivation of Stalled Replication Forks","volume":"23","author":"Yang","year":"2004","journal-title":"Oncogene"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s0891-5849(00)00461-5","article-title":"Peroxynitrite Induces GADD34, 45, and 153 VIA P38 MAPK in Human Neuroblastoma SH-SY5Y Cells","volume":"30","author":"Oh-Hashi","year":"2001","journal-title":"Free Radic Biol Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.arr.2011.09.003","article-title":"Gadd45 Proteins: Relevance to Aging, Longevity and Age-Related Pathologies","volume":"11","author":"Moskalev","year":"2012","journal-title":"Ageing Res Rev"},{"key":"B46","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13046-016-0461-5","article-title":"Sirtuins in Metabolism, DNA Repair and Cancer","volume":"35","author":"Mei","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb00731.x","article-title":"Differential Regulation of the MAP, SAP and RK\/p38 Kinases by Pyst1, a Novel Cytosolic Dual-Specificity Phosphatase","volume":"15","author":"Groom","year":"1996","journal-title":"EMBO J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4161\/cc.7.8.5783","article-title":"IAPs: More Than Just Inhibitors of Apoptosis Proteins","volume":"7","author":"Dubrez-Daloz","year":"2008","journal-title":"Cell Cycle"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80390-8","article-title":"TRAF2 Is Essential for JNK But Not NF-\u03baB Activation and Regulates Lymphocyte Proliferation and Survival","volume":"7","author":"Lee","year":"1997","journal-title":"Immunity"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80391-x","article-title":"Early Lethality, Functional NF-\u03baB Activation, and Increased Sensitivity to TNF-Induced Cell Death in TRAF2-Deficient Mice","volume":"7","author":"Yeh","year":"1997","journal-title":"Immunity"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.7.1233","article-title":"Requirement of Tumor Necrosis Factor Receptor-Associated Factor (TRAF)6 in Interleukin 17 Signal Transduction","volume":"191","author":"Schwandner","year":"2000","journal-title":"J Exp Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.383","article-title":"Syk Mediates IL-17-Induced CCL20 Expression by Targeting Act1-Dependent K63-Linked Ubiquitination of TRAF6","volume":"135","author":"Wu","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12820","article-title":"TWEAK\/Fn14 Activation Induces Keratinocyte Proliferation Under Psoriatic Inflammation","volume":"25","author":"Cheng","year":"2016","journal-title":"Exp Dermatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-3233(04)69005-X","article-title":"Functions of DNA Polymerases","volume":"69","author":"Bebenek","year":"2004","journal-title":"Adv Protein Chem"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1996.0490","article-title":"Cloning and Characterization of the Human Mitochondrial DNA Polymerase, DNA Polymerase Gamma","volume":"36","author":"Ropp","year":"1996","journal-title":"Genomics"},{"key":"B56","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1667\/RR0706.1","article-title":"DNA Polymerases and Human Diseases","volume":"166","author":"Sweasy","year":"2006","journal-title":"Radiat Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e1007065","DOI":"10.1371\/journal.ppat.1007065","article-title":"PARP1 Depletion Improves Mitochondrial and Heart Function in Chagas Disease: Effects on POLG Dependent mtDNA Maintenance","volume":"14","author":"Wen","year":"2018","journal-title":"PLoS Pathog"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.694793\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T18:04:35Z","timestamp":1626977075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.694793\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":57,"alternative-id":["10.3389\/fonc.2021.694793"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.694793","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,22]]},"article-number":"694793"}}